{
    "clinical_study": {
        "@rank": "8240", 
        "acronym": "AH", 
        "arm_group": [
            {
                "arm_group_label": "IDN-6556", 
                "arm_group_type": "Experimental", 
                "description": "IDN-6556 capsules, 25 mg BID"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo capsules BID"
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of the study is to test if taking a study drug called emricasan (also known\n      as IDN-6556 and PF-03491390) will affect overall patient survival after one month of\n      treatment."
        }, 
        "brief_title": "Study of IDN-6556 in Patients With Severe AH and Contradictions to Steroid Therapy", 
        "completion_date": {
            "#text": "January 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Alcoholic Hepatitis", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Alcoholic"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study will also see if overall patient survival is affected at 6 months, and if the\n      study drug improves liver functioning."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients 21 years of age or older\n\n          -  Patients with alcoholic hepatitis defined as:\n\n               1. History of heavy alcohol abuse use: >40 g/day in females and >60 g/day in males\n                  for a minimum period of 6 months\n\n               2. Consumed alcohol within 6 weeks of entry into the study\n\n               3. Biochemical parameters of severe disease as evidenced by MELD score >20 but <35\n\n          -  Patients with established contraindications to steroid use including but not limited\n             to the following:\n\n               1. GI bleed\n\n               2. Active infection, including spontaneous bacterial peritonitis, based on positive\n                  blood culture, urine culture, or chest x-ray (if positive, must have been on\n                  antibiotics for at least 24 hours prior to study entry)\n\n               3. Acute pancreatitis (increased lipase > 3x ULN or radiologic evidence)\n\n               4. Positivity for hepatitis B (HBsAg+) or C virus (HCV+), and\n\n               5. Renal failure (must have eGFR (estimated glomerular filtration rate) >15 mL/min,\n                  and not be on dialysis at time of entry into study)\n\n        Exclusion Criteria:\n\n          -  Other or concomitant cause of liver disease as a result of:\n\n               1. Autoimmune liver disease (positive anti-mitochondrial antibody and smooth muscle\n                  antibody, positive reading on anti-nuclear antibody titer >1:160)\n\n               2. Metabolic liver disease (abnormal ceruloplasmin levels)\n\n               3. Vascular liver disease\n\n               4. Drug induced liver disease\n\n          -  Sepsis as evidenced by positive blood or urine culture, pneumonia as confirmed by\n             x-ray\n\n          -  History of renal transplant and/or severe renal impairment defined as eGFR of \u226415\n             mL/min, or on dialysis at time of entry into study\n\n          -  Diagnosed or suspected systemic lupus erythematosus (SLE) and/or rheumatoid arthritis\n             (RA)\n\n          -  Hepatocellular carcinoma (HCC) at entry into the study\n\n          -  Active non-liver malignancies other than curatively treated skin cancer (basal cell\n             or squamous cell carcinomas)\n\n          -  Patients requiring the use of vasopressors or inotropic support\n\n          -  Liver biopsy, if carried out, showing findings not compatible with alcoholic\n             hepatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01912404", 
            "org_study_id": "IDN-6556-04", 
            "secondary_id": "5U01AA021788"
        }, 
        "intervention": {
            "arm_group_label": "IDN-6556", 
            "description": "25 mg BID for 28 days", 
            "intervention_name": "IDN-6556", 
            "intervention_type": "Drug", 
            "other_name": [
                "emricasan", 
                "PF-03491390"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "alcoholic hepatitis", 
        "lastchanged_date": "February 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Indianapolis", 
                        "country": "United States", 
                        "state": "Indiana", 
                        "zip": "46202"
                    }, 
                    "name": "Indiana University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Mayo Clinic"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Richmond", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23298"
                    }, 
                    "name": "Virginia Commonwealth University"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Corticosteroid Therapy", 
        "overall_contact": {
            "email": "gburgess@conatuspharma.com", 
            "last_name": "Gary Burgess, MD", 
            "phone": "+44 7879602104"
        }, 
        "overall_official": {
            "affiliation": "Conatus Pharmaceuticals", 
            "last_name": "Gary Burgess, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Survival", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01912404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "measure": "Change in liver function scores", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }, 
            {
                "measure": "Worsening of pre-existing organ failure or development of new organ failure", 
                "safety_issue": "Yes", 
                "time_frame": "28 days"
            }
        ], 
        "source": "Conatus Pharmaceuticals Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "National Institute on Alcohol Abuse and Alcoholism (NIAAA)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Conatus Pharmaceuticals Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}